Seed funding
IP Group plc has made a further investment in Tissue Regenix Ltd, a spin-out from the University of Leeds that is developing human tissue products for use in orthopaedic and heart surgery.
The company is based on research carried out at the university’s faculties of engineering and biological sciences. It claims that its acellular tissue matrix products behave like native tissue in almost every respect, are compatible with all blood and skin types, do not calcify, and are able to regenerate themselves.
The new funding of £685,000 comes from IP Group and the university seed fund White Rose Technology.
Tissue Regenix was spun out of the university in May 2006 with early stage funding from IP Group. It is based on research which has received over £2 million public funding in the past five years.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
